Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antigenics, a biotechnology company, has announced that Oncophage has been granted a positive recommendation for orphan drug designation for the treatment of glioma by the Committee for Orphan Medical Products of the European Medicines Agency.
Subscribe to our email newsletter
This designation provides Antigenics with, among other benefits, 10 years of potential market exclusivity if the product is approved for marketing in the EU.
This is the second indication for which the European Medicines Agency has granted orphan drug status to Oncophage. In April 2005, Oncophage received orphan drug designation in the EU for the treatment of renal cell carcinoma.
Garo Armen, chairman and CEO of Antigenics, said: “We are committed to supporting the evaluation of Oncophage in patients diagnosed with glioma, as this remains a life-threatening disease with limited treatment options. Furthermore, orphan drug status has the potential to accelerate the development of Oncophage in this patient population, which is critical given the poor survival rates.”